Elisabeth I. Heath, M.D.

Contact Us for the Latest Status

• Phase 1, Dose-Escalation Study Of KTX2001 (an NSD2 Inhibitor) Alone And In Combination With Darolutamide For Metastatic Castration-Resistant Prostate Cancer Rochester, Minn.

  Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective in treating metastatic castration-resistant prostate cancer, and measuring how the drug(s) behaves in the body.